MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies

Cancer patients with advanced disease are characterized by intrinsic challenges in predicting drug response patterns, often leading to ineffective treatment. Current clinical practice for treatment decision-making is commonly based on primary or secondary tumour biopsies, yet when disease progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, Fabienne D., Scheidmann, Manuel C., Ozimski, Lauren L., Kling, André, Armbrecht, Lucas, Ryser, Till, Krol, Ilona, Strittmatter, Karin, Nguyen-Sträuli, Bich Doan, Jacob, Francis, Fedier, André, Heinzelmann-Schwarz, Viola, Wicki, Andreas, Dittrich, Petra S., Aceto, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763115/
https://www.ncbi.nlm.nih.gov/pubmed/36561926
http://dx.doi.org/10.1038/s41378-022-00467-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763115/
https://www.ncbi.nlm.nih.gov/pubmed/36561926
http://dx.doi.org/10.1038/s41378-022-00467-y

Ejemplares similares